Oncology's ESMO Week Is Priced on Pipelines, Not Profits: Summit's Filings Show What the Bet Costs

The money behind the catalysts

Cancer-drug news this week is a run of regulatory and conference headlines. The most useful number for an investor is not in any of them. It is what it costs a company to stay in the race before a product sells. Summit Therapeutics, named in our narrative as part of a new trial collaboration with AstraZeneca and Daiichi Sankyo, is the one company in this story whose financials we can check line by line against SEC filings. It reported zero revenue in both FY2023 and FY2024.¹ Its net loss was $614.9 million in FY2023, $221.3 million in FY2024 and $1,079.6 million in FY2025.¹ The FY2025 loss is about 4.9 times the FY2024 loss, a ratio we calculated from the two verified figures. Loss per share moved from -$0.99 to -$0.31 and then to -$1.44.¹

This is a bet on a drug working, not a business earning money. We found no terms for the Summit, AstraZeneca and Daiichi Sankyo collaboration in our material, so we cannot say who pays for what.⁸

Real cash out of the door, and an unexplained gap

The net loss is not the same as cash leaving. Operating cash flow was -$76.8 million in FY2023, -$142.1 million in FY2024 and -$322.9 million in FY2025.¹ The FY2025 cash burn is therefore far smaller than the FY2025 headline loss. Our checked data does not explain the difference. It could come from items that involve no cash, but we cannot confirm that from what we hold, and we are not guessing at it. Capital spending on equipment and facilities is tiny: $128,000 in FY2023, $139,000 in FY2024 and $657,000 in FY2025.¹ This is a company spending on research and trials, not on building things.

How the cash balance moved

Year-end cash was $71.4 million in FY2023, $104.9 million in FY2024 and $225.3 million in FY2025.¹ The quarterly path is more uneven. Cash was $297.9 million in Q2 2025 and $238.6 million in Q3 2025.¹ It was $106.5 million in Q1 2026, then $419.4 million in Q2 2026.¹ Cash fell sharply through the winter and then more than tripled in a single quarter. The verified data records the balances, not the reason. A rise of that size normally means new money came in, but our filings extract does not say from where, so treat that as an open question rather than a finding.

Read the cash figure against the burn. A year of FY2025-sized operating cash outflow is $322.9 million, so the Q2 2026 balance of $419.4 million covers roughly 15 months at that pace. This is our own arithmetic, not a company statement, and spending will change as trials expand.¹

The commercial side: one company that is actually selling

Novocure shows what a revenue line looks like. It reported quarterly net revenues of $184 million, up 16% year over year, with 18% growth in global active patients.² It also received a CE Mark for Optune Pax in locally advanced pancreatic cancer and reported more than 280 active patients on it as of June 30, 2026.² CEO Frank Leonard said: "This was our strongest quarter to date, with record net revenues and active patients on therapy."² That is the contrast with Summit. One company is already growing sales, and the other is still funding the research that might create them.

The ADC theme and the regulatory run

Antibody-drug conjugates are the main theme in our narrative.⁸ AbbVie announced new and updated data across seven assets in lung, colorectal, ovarian, prostate and gastric cancers, its largest ESMO program to date.⁷ Akari Therapeutics is positioning its early-stage AKTX-101, with a planned Phase 1 start in mid-2027, around patients whose cancer has stopped responding to existing ADCs.³ The company says these patients are a growing unmet need and an opportunity that current and most future ADCs will not be able to reach.³ That is a company's own pitch for its drug. It is not independent evidence of demand.

The regulatory news is more concrete. The EMA's CHMP gave a positive opinion for RASONQUE (daraxonrasib), an oral once-daily tablet for metastatic pancreatic adenocarcinoma, and for an alternative Libtayo dosing schedule.⁷ In July it also backed Gilead's Trodelvy plus Keytruda in first-line triple-negative breast cancer.⁴ A CHMP opinion is a recommendation, and a final European authorization decision follows separately. Our narrative also cites an FDA approval for Tecentriq in dMMR colon cancer, but our material contains no source document for it.⁸

Real-world evidence is part of the picture too. Kyowa Kirin's final MINT analysis covered 109 patients at 18 German centres and showed a median time to next treatment of 14.9 months for mogamulizumab.⁶

AI discovery: promising, but the source is weak

AstraZeneca's AI and robotics 'lab of the future' push is the longer-term story. Puja Sapra describes it this way: "Where a self-driving car uses sensors and models to navigate its environment, this system uses AI to make predictions, robotic systems to execute experiments, and instruments to generate data."⁵ She is also candid about the limit: "One of the hardest problems in de novo design is predicting whether a computationally generated molecule will be safe in the human body."⁵ No dollar figure for this spending appears in our material, so we cannot size it. This is also our least reliable source. Our checks found that 0% of 11 claims checked from the MIT Technology Review article held up, so it should be read as a description of intent, not proof of results.⁵ The news-wire sources behind the other items held up better, at 56% of 5,087 claims checked, which still means nearly half did not.²

Deals: the signal with the least detail

Our narrative points to McKesson and CD&R buying Option Care Health as evidence of capital flowing into the sector.⁸ We hold no price or terms for that deal, only that Option Care is based in Bannockburn, IL.⁸ We would not read a valuation into it.

What to watch

• Dates. Our brief says ESMO runs October 23-24, while our event record says October 23-27 in Madrid.⁷ Moderna and Merck plan to present detailed intismeran results on October 24.⁷
• Summit's next filing. Look for what explains the jump in cash to $419.4 million, and whether the gap between net loss and cash burn narrows.¹
• Authorizations. Watch whether the CHMP opinions turn into final European authorizations.⁷
• Collaboration terms. Watch whether the Summit, AstraZeneca and Daiichi Sankyo collaboration discloses any financial terms.⁸